Image: GloFish
Getty Images file
GloFish were originally intended to help scientists study pollution, but now they are being marketed as the first genetically altered house pet.
updated 1/15/2004 12:11:16 PM ET 2004-01-15T17:11:16

A federal judge is weighing a lawsuit by two public interest groups that want to block sales of fluorescent zebra fish — the nation’s first biotech household pet.

The lawsuit, filed Wednesday, asks the judge to order that the Food and Drug Administration and the Department of Health and Human Services to halt sales of the trademarked GloFish until the government regulates the genetically modified animal.

The normally black-and-silver zebra fish glow bright red under black or ultraviolet light thanks to a gene transplanted from a sea anemone. Sales of the Florida-grown fish began this month everywhere in the country except California, which banned the fish in December.

Not regulating the GloFish sets “a dangerous precedent for all future gene-altered animals, whether created as food or pet fads,” said Joseph Mendelson, legal director for the Center for Food Safety, which filed the suit along with the Center for Technology Assessment.

The FDA said last month it will not regulate the fish because it is not intended for human consumption. A spokeswoman said Wednesday the FDA stands by that statement.

GloFish are a product of Yorktown Technologies LLP of Austin, Texas. The company’s chief executive, Alan Blake, said scientific studies have shown the fish are safe and the lawsuit is without merit.

The federal suit, filed in Washington, D.C., alleges the benign fluorescing gene was inserted using other genes derived from animal and human viruses as well as antibiotic resistant bacteria.

The suit alleges the hidden genes can threaten human and animal health if the biotech fish are released and consumed by other fish that eventually are eaten by humans.

Background on the lawsuit is online at www.centerforfoodsafety.org and on the company's position at www.glofish.com/ethics.asp

© 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments